18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.
Checked against the public recordLast updated Apr 9, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Andrei Iagaru
- Interventions being studied
- Diagnostic Test: Computed Tomography; Drug: Fludeoxyglucose F-18; Drug: Fluorine F 18 L-glutamate Derivative BAY94-9392; Diagnostic Test: Positron Emission Tomography (PET/CT)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be eligible if the dominant nodule is 7 to 30 mm * Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule) * Current or former cigarette smoker, with \>= 20 pack years * Documented informed consent Exclusion Criteria: * History or previous diagnosis of lung cancer * Cancer diagnosis within the last 5 years * Pregnant or nursing
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Stanford Cancer Institute Palo AltoPalo Alto, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Apr 9, 2025. Always confirm current availability with the study team.